Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 241

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 241
---
 been identified and presented to provide relevant information necessary for an understanding of the Combined Company after giving effect to the Business Combination. OmnigenicsAI, and its subsidiary, and the SPAC have not entered into related party transactions prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. Please refer to “ Certain APx Relationships and Related Person Transactions.” This information should be read together with the Company’s and SPAC’s financial statements and related notes, “ APx Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information included elsewhere in this proxy statement/prospectus. The selected unaudited pro forma combined financial information is presented for illustrative purposes only. Such information is only a summary and should be read in conjunction with the section titled “ Unaudited Pro Forma Combined Financial Information.” The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma combined financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the Combined Company will experience. The unaudited pro forma combined financial statements do not necessarily reflect what the Combined Company’s financial condition or results of operations would have been had the Business Combination occurred on said date. The unaudited pro forma combined financial information also may not be useful in predicting the future financial condition and results of operations of the Combined Company. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma combined financial information and are subject to change as additional information becomes available and analyses are performed. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. Such differences might include but are not limited to the estimated fair value of OmnigenicsAI equity consideration, the estimated fair value of Founder Shares, the estimated fair value of the APx public and private warrant liabilities and the exercise of redemption rights in respect of Public Shares. Rounding Certain figures (including percentage amounts) included in this pro forma combined financial information have been rounded for presentation purposes. Percentage figures and totals included in said pro forma information have, in some cases, been calculated based on such figures prior to rounding. For this reason, certain percentage and total amounts may vary from those obtained by performing the same calculations using the figures in the historical financial